ClinicalTrials.gg
CompletedNCT02148133Updated May 3, 2019Results posted

A Study to Assess the Safety and Efficacy of Eltrombopag in Japanese Subjects With Refractory, Moderate or More Severe Aplastic Anemia

A Phase 2 interventional study of Eltrombopag 12.5 mg and Eltrombopag 25 mg in Cytopaenia, sponsored by Novartis Pharmaceuticals. Completed at 12 sites in Japan. Open to participants aged 18 Years to 79 Years. Per ClinicalTrials.gov, last updated 2019-05-03.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
21
Allocation
Not applicable
Ages
18 Years to 79 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 17 studies testing eltrombopag in Anemia, Aplastic — 3 open to participants now, 3 under way, 1 of them phase 3. eltrombopag · Anemia, Aplastic.

Enrollment
11th of 17
21 · median 36
Started
2014
the only one that year
Phase 2
11 of 17
1 open now
Registered
6th of 17
by date
Lead sponsor
6 of 17
Novartis Pharmaceuticals

Among the 17 studies testing eltrombopag in Anemia, Aplastic, this one is the 11th largest by enrollment, is the only one that started in 2014, is one of 11 in phase 2, and was the 6th registered.

Anemia, Aplastic

372 studies on the registry are indexed under Anemia, Aplastic; 99 are open to participants now.

Browse Anemia, Aplastic studies →

Open to participants now

3 of the 17 studies testing eltrombopag in Anemia, Aplastic are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About eltrombopag

eltrombopag: first FDA approval 2008 (PROMACTA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 59 Anemia, Aplastic studies recruiting now, 21 (36%) set no upper age limit and 30 (51%) stop at 75 or younger; 38 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 79 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing eltrombopag in Anemia, Aplastic, or all of them as a file.
02

Study summary

This was a non-randomized, open-label, phase II study to assess the efficacy and safety of eltrombopag in Japanese moderate or more severe aplastic anemia (AA) subjects with a platelet count \<30,000/microliter who were refractory to anti-thymocyte globulin (ATG)-based immunosuppressive therapy (IST), who have relapsed after ATG-based IST, or who are ineligible for ATG-based IST.

Eltrombopag was expected to improve trilineage blood cells and decrease transfusion frequency based on the result from the previous study in patients with severe AA. This study used the hematologic response rate, defined as the proportion of subjects showing improvement in at least one of the three blood cell lineages or a decrease in blood transfusion volume, as the primary endpoint.

A total of 36 subjects were screened and 21 were enrolled in the study. Treatment with eltrombopag started at 25 milligram (mg)/day and increased by 25 mg/day every 2 weeks according to the platelet count up to 100 mg/day. Response assessment was performed at 3 months after starting the study treatment (Week 13). Subjects in whom the treatment was assessed as effective continued with the study treatment. Subjects in whom the treatment was assessed as effective (when meeting any of the response criteria) at 6 months after starting the study treatment (Week 26) might enter the extension phase and continue the treatment with eltrombopag. The primary endpoint was the hematologic response rate at Week26.

03

Conditions studied

  • Cytopaenia

Keywords

  • Eltrombopag
  • Aplastic Anemia (AA)
  • Thrombocytopenia
  • Thrombopoietin
  • Bone Marrow
  • Bone Marrow Biopsy
  • Hematopoietic Stem Cells
  • Mature Blood Cells
  • Pancytopenia
  • Leukopenia
  • Platelets
04

Who can participate

Ages eligible
18 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Subject has given written . If a subject is under 20 years, both the subject and the subject's legally acceptable representative have to give informed consent.
  • Japanese subjects aged >=18 and \<80 years at the time of informed consent.
  • Diagnosis of moderate (stage II) or more Aplastic Anemia (AA) with count \<30,000/microliter (based on the diagnosis criteria of AA established by the Study Group on Idiopathic Hematopoietic Disorder as a part of Research on Measures for Intractable Diseases supported by Health and Labor Science Research Grants).
  • Subjects who became to Anti-thymocyte globulin (ATG)-based therapy (IST), who have relapsed after ATG-based IST, or who are ineligible for ATG-based IST. Note: Refractory or relapsed subjects to whom re-treatment with ATG is indicated should not be enrolled in the study. Subjects who have a sibling donor with matched human leukocyte antigen (HLA) should not be enrolled in the study. However, such subjects may be enrolled if the disease relapsed after hematopoietic stem cell transplantation (), if HSCT is not indicated, or the subject does not want to undergo HSCT.
  • Adequate organ function at screening and Day 1 as defined as follows: (ALT) and aspartate aminotransferase (AST) \<=3 × central laboratory (ULN); Creatinine, total , and alkaline phosphatase (ALP) \<1.5 × central laboratory ULN (total bilirubin \<2.5 × central laboratory ULN with Gilbert's Syndrome)
  • (ECOG) Performance Status (PS): 0 or 1
  • Subjects with corrected for heart rate by Fridericia's formula (QTcF) \<450 milliseconds (msec) or QTcF\<480 msec with branch block. Corrected QT interval duration (QTc) is QT interval corrected by Fridericia formula (QTcF), machine or manual over read. QTcF is based on single or averaged QTc value of triplicate (ECG).
  • Subjects who meet one of the following conditions: Male subjects who have a female partner of must either have a prior vasectomy or agree to use an acceptable from time of enrollment in the study until 16 weeks after the last dose of eltrombopag (based upon the lifecycle of sperm); Female subjects of non-childbearing potential (who are physiologically unable to become pregnant) defined as: Premenopausal women with documented bilateral oophorectomy, bilateral tubal ligation, or hysterectomy; or women after at least 12 months of natural amenorrhea [if uncertain, postmenopausal state should be confirmed by hematology result of follicle stimulating hormone (FSH) >40 milli international unit /milliliter (mIU/mL) or estradiol \<40 picogram (pg)/mL (\<140 picomole /Liter (pmole/L)].; Female subjects of childbearing potential: Defined as those not meeting the definition of non-childbearing potential. Female subjects of childbearing potential must have a negative serum human chorionic gonadotropin (hCG) or urine pregnancy test within 7 days prior to the first dose of study treatment. It is recommended that the pregnancy test should be performed as close as possible to the first dose of study treatment. Female subjects with a positive pregnancy test must be excluded from the study. Subjects with a negative pregnancy test must use acceptable contraception including abstinence after the pregnancy test. Subjects must agree to use the acceptable contraception including abstinence from 14 days prior to the first dose of study treatment until 28 days after the last dose of eltrombopag.

Key Exclusion Criteria:

  • Treatment with ATG in the past 12 months. Note: Subjects who are receiving cyclosporine or anabolic steroids (excluding danazol) at a stable dose may be enrolled if laboratory values are stable at screening.
  • Congenital aplastic anemia (e.g., Fanconi anemia, congenital dyskeratosis)
  • Paroxysmal nocturnal hemoglobinuria (PNH) granulocyte clone size determined by flow cytometry >=50%
  • Presence of chromosomal aberration (-7/7q- detected by fluorescence in situ hybridization (FISH), or other aberrations detected by Giemsa (G)-band staining) Note: Subjects with the result by G-band staining (bone marrow aspiration) not adopted into the abnormal clone definition of An International System for Human Cytogenetic Nomenclature (ISCN) can be enrolled as no chromosomal aberration.
  • Past history of thromboembolism or current use of anticoagulants. Note: Subjects with antiphospholipid antibody syndrome (APS) should not be enrolled.
  • Past or current history of malignant tumor. Note: Subjects who have a history of completely resected malignant tumor and have been disease-free for 5 years are eligible.
  • Subjects who test positive for surface (HBs) antigen, virus (HCV) antibody, or (HIV) antibody at screening. Note: Subjects with inactive hepatitis B may be enrolled. Judgment of inactive hepatitis B will be done by the medical advisor.
  • Subjects with concurrent uncontrollable severe infection (e.g., sepsis)
  • Hepatic cirrhosis
  • Cardiac disorder (congestive heart disease of (NYHA) functional classification Grade II/III/IV), or arrhythmia with a risk of thrombosis (e.g., atrial fibrillation). Note: Subjects with NYHA Grade II due to cardiac disorder should not be enrolled but those with NYHA Grade II due to Aplastic Anemia (AA) may be enrolled.
  • Alcohol or drug abuse
  • Pregnant women (a positive serum or urine pregnancy test within 7 days prior to the first dose of study treatment) or lactating women. Note: Female subjects who are lactating are eligible to participate if they discontinue nursing prior to the first dose of study treatment and refrain from nursing until 5 days after the treatment completion.
  • Past history of immediate or delayed to compounds chemically similar to eltrombopag or their activators
  • Treatment with another product within 30 days or the period 5-fold longer than the half-life of the investigational product, whichever longer, prior to the first dose of eltrombopag
  • Prior treatment with eltrombopag, romiplostim, or any other Thrombopoietin (TPO) receptor agonist
  • Use of prohibited concomitant medications.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
21 participants (actual)

Study arms

  • Experimental
    Eltrombopag

    Subjects were assigned the investigational product (eltrombopag 25 mg/day) orally once a day under fasting condition. The dose adjustment was done every 2 weeks according to the platelet count (increased by eltrombopag 25 mg/day every 2 weeks according to the platelet count up to 100 mg/day).

    Drug: Eltrombopag 12.5 mg · Drug: Eltrombopag 25 mg

Interventions

  • White, round, film-coated tablets containing 12.5 mg of eltrombopag free acid (SB-497115-GR, eltrombopag) in each tablet

    Also known as: Revolade

  • White, round, film-coated tablets containing 25 mg of eltrombopag free acid (SB-497115-GR, eltrombopag) in each tablet

    Also known as: Revolade

06

What researchers measure

Primary outcomes

  1. Hematological Response at Week 26

    Hematologic response rate at 6 months (at WeeK 26) after the start of study treatment was defined as the percentage of subjects who met any of the response criteria (Platelet count, Hemoglobin level, Neutrophil count). 1 ) Platelet count: an increase from baseline by 20,000/μL or more (In the absence of platelet transfusion), or no platelet transfusion requirements for 8 weeks; 2) Hemoglobin: When the baseline hemoglobin level is \<9 g/dL: Without RBC transfusion at baseline, an increase from baseline by 1.5 g/dL or more; With RBC transfusion at baseline, a decrease of at least 4 units in RBC transfusions in the post-treatment 8-week period compared to the pre-treatment 8-week period (1 unit = RBC derived from 200 mL blood); 3) Neutrophil count: an increase from baseline by 500/μL or more (in the absence of granulocyte colony-stimulating factor (G-CSF)), or (if \< 500/μL at baseline) an increase by 100 % or more. Only descriptive analysis done.

    Time frame: D183 (Week 26)

Secondary outcomes

  1. Change in Platelet Count From Baseline in the Absence of Platelet Transfusion Over Time

    The changes in observed values for Platelet Count were summarized. The measurements were followed up to Week 26 and thereafter in the extension part (Up to the launch of the product after approval, which will be approximately up to two and a half years). Only descriptive analysis done.

    Time frame: Up to 2.5 years

  2. Change in Hemoglobin From Baseline in the Absence of Red Blood Cell (RBC) Transfusion Over Time

    The changes in observed values for Hemoglobin were summarized. The measurements were followed up to Week 26 and thereafter in the extension part (Up to the launch of the product after approval, which will be approximately up to two and a half years). Only descriptive analysis done.

    Time frame: Up to 2.5 years

  3. Change in Neutrophil Count From Baseline in the Absence of Granulocyte-colony Stimulating Factor (G-CSF) Over Time

    The changes in observed values for Neutrophil Count were summarized. The measurements were followed up to Week 26 and thereafter in the extension part (Up to the launch of the product after approval, which will be approximately up to two and a half years). Only descriptive analysis done.

    Time frame: Up to 2.5 years

  4. Hematological Response at Week 13 in Terms of the Platelet Count, Hemoglobin Level and Neutrophil Count

    The frequency and percentage were calculated with 95% confidence interval (CI) of responses (which meet each response criteria) of platelet count, hemoglobin and neutrophil count at Week 13.

    Time frame: Week 13

  5. Duration of Hematological Response in Participants Who Responded at the Week 13

    The duration of haematological response was defined, for subjects who responded at the Week 13 visit, as the number of months from the first date of a response until the first date of a relapse or the date the subject was last assessed. Only subjects with at least 2 response assessments were included in the duration of response assessment. The measurements were followed up to Week 26 and thereafter in the extension part (Up to the launch of the product after approval, which will be approximately up to two and a half years). Only descriptive analysis done.

    Time frame: Up to 2.5 years

  6. Volume of (Platelet and RBC) Transfusion in Each Period

    The amount of blood transfusion (platelets, RBC) were summarized. The measurements were followed up to Week 26 and thereafter in the extension part (Up to the launch of the product after approval, which will be approximately up to two and a half years). Only descriptive analysis done.

    Time frame: Day 1, Day 92 (Week 13), Day 183 (Week 26), Extension W39 and Extension W52

  7. Frequency of (Platelet and RBC) Transfusion in Each Period

    The frequency of blood transfusion (platelets, RBC) were summarized. The measurements were followed up to Week 26 and thereafter in the extension part (Up to the launch of the product after approval, which will be approximately up to two and a half years). Only descriptive analysis done.

    Time frame: Day 1, Day 92 (Week 13), Day 183 (Week 26), Extension W39 and Extension W52

  8. Percentage of Participants With Reduced Volume of Transfusion (Platelet and RBC)

    The proportion of the participants for whom the amount of blood transfusion (platelets and RBC) is decreased was measured and reported as a percentage. The measurements were followed up to Week 26 and thereafter in the extension part (Up to the launch of the product after approval, which will be approximately up to two and a half years). Only descriptive analysis done. This analysis was performed for the subjects who were baseline transfusion dependent.

    Time frame: Up to 2.5 years

  9. Percentage of Participants Who Become Transfusion (Platelet and RBC) Independent

    The proportion of participants for whom blood transfusion (platelets and RBC) became unnecessary was measured and reported as a percentage. The measurements were followed up to Week 26 and thereafter in the extension part (Up to the launch of the product after approval, which will be approximately up to two and a half years). Only descriptive analysis done. This analysis was performed for the subjects who were baseline transfusion dependent.

    Time frame: Up to 2.5 years

  10. Long-term Safety and Tolerability of Eltrombopag

    The frequency and percentage of subjects who experienced adverse events (AEs), serious adverse events (SAEs) and deaths by primary system organ class (SOC) and MedDRA preferred term were summarized.

    Time frame: Up to 30 days after last dose of study treatment

  11. Number of Participants With Bleeding Events and Severity of Bleeding

    The measurements were followed up to Week 26 and thereafter in the extension part.

    Time frame: Up to 30 days after last dose of study treatment

  12. Maximum Observed Plasma Concentration (Cmax) for Eltrombopag

    At some study sites, full blood sampling for pharmacokinetic (PK) evaluation of Eltrombopag was performed on Day 14 to calculate Cmax, tmax, AUC(0-t), and AUC(0-tau). PK parameters were calculated from plasma concentration-time data using non-compartmental methods.

    Time frame: Day 14 at 25 mg QD (-0.05, 0.15, 0.30, 0.45, 1.00, 1.30 and 24.00), at 50,75 and 100 mg QD (pre-dose)

  13. Time to Reach the Maximum Plasma Concentration (Tmax) for Eltrombopag

    At some study sites, full blood sampling for pharmacokinetic (PK) evaluation of Eltrombopag was performed on Day 14 to calculate Cmax, tmax, AUC(0-t), and AUC(0-tau). PK parameters were calculated from plasma concentration-time data using non-compartmental methods.

    Time frame: Day 14 at 25 mg QD (-0.05, 0.15, 0.30, 0.45, 1.00, 1.30 and 24.00), at 50,75 and 100 mg QD (pre-dose)

  14. Area Under the Concentration-time Curve From Time Zero (Pre-dose) to Last Time of Quantifiable Concentration Within a Subject Across All Treatments (AUC 0-t) and Over the Dosing Interval (AUC 0-tau) for Eltrombopag

    At some study sites, full blood sampling for pharmacokinetic (PK) evaluation of Eltrombopag was performed on Day 14 to calculate Cmax, tmax, AUC(0-t), and AUC(0-tau). PK parameters were calculated from plasma concentration-time data using non-compartmental methods.

    Time frame: Day 14 at 25 mg QD (-0.05, 0.15, 0.30, 0.45, 1.00, 1.30 and 24.00), at 50,75 and 100 mg QD (pre-dose)

  15. Mean Change in Eltrombopag Concentration in Pharmacokinetic Serum Samples Over Time at Days 14 and 15

    At every study center, blood samples was be collected on Day 15 of multiple doses of eltrombopag 25 mg to determine the plasma eltrombopag concentration prior to the next dose (trough concentration). In addition, one-point pre-dose blood sampling was performed at every study center on Day 15 of multiple doses of eltrombopag 50 mg, 75 mg and 100 mg to determine trough concentrations. PK parameters were calculated from plasma concentration-time data using non-compartmental methods.

    Time frame: Day 14 (pre-dose, 1, 2, 4, 6, 8 and 24 post-dose), Day 15 (pre-dose)

07

Results

Posted May 3, 2019

Participant flow

The study took place in 12 clinical sites in Japan

Participant flow — Overall Study
MilestoneEltrombopag
Started21
Safety set (ss)21
Pharmacokinetic analysis set (pas)21
Completed16
Not completed5
Withdrew: Investigator discretion1
Withdrew: Lack of efficacy1
Withdrew: Protocol deviation1
Withdrew: Protocol-defined stopping criteria2

Outcome measures

PrimaryHematological Response at Week 26

Hematologic response rate at 6 months (at WeeK 26) after the start of study treatment was defined as the percentage of subjects who met any of the response criteria (Platelet count, Hemoglobin level, Neutrophil count). 1 ) Platelet count: an increase from baseline by 20,000/μL or more (In the absence of platelet transfusion), or no platelet transfusion requirements for 8 weeks; 2) Hemoglobin: When the baseline hemoglobin level is \<9 g/dL: Without RBC transfusion at baseline, an increase from baseline by 1.5 g/dL or more; With RBC transfusion at baseline, a decrease of at least 4 units in RBC transfusions in the post-treatment 8-week period compared to the pre-treatment 8-week period (1 unit = RBC derived from 200 mL blood); 3) Neutrophil count: an increase from baseline by 500/μL or more (in the absence of granulocyte colony-stimulating factor (G-CSF)), or (if \< 500/μL at baseline) an increase by 100 % or more. Only descriptive analysis done.

Time frame:
D183 (Week 26)
Reported as:
Number · Percentage of participants
Hematological Response at Week 26
Percentage of participantsEltrombopag
Hematological Response at Week 2647.6 (25.7 to 70.2)
SecondaryChange in Platelet Count From Baseline in the Absence of Platelet Transfusion Over Time

The changes in observed values for Platelet Count were summarized. The measurements were followed up to Week 26 and thereafter in the extension part (Up to the launch of the product after approval, which will be approximately up to two and a half years). Only descriptive analysis done.

Time frame:
Up to 2.5 years
Reported as:
Mean · Giga/Liter (Gi/L)
Change in Platelet Count From Baseline in the Absence of Platelet Transfusion Over Time
Giga/Liter (Gi/L)Eltrombopag
Baseline12.19 ± 7.155
D92 Week136.32 ± 7.698
D183 Week2613.09 ± 14.015
Extension W3923.50 ± 22.037
Extension W5221.50 ± 15.720
Extension W7836.69 ± 23.798
Extension W10435.79 ± 21.389
Extension W13042.79 ± 28.795
Extension W15625.50 ± NA
Withdrawal8.81 ± 19.387
Last Assessment On-Therapy18.38 ± 24.017
SecondaryChange in Hemoglobin From Baseline in the Absence of Red Blood Cell (RBC) Transfusion Over Time

The changes in observed values for Hemoglobin were summarized. The measurements were followed up to Week 26 and thereafter in the extension part (Up to the launch of the product after approval, which will be approximately up to two and a half years). Only descriptive analysis done.

Time frame:
Up to 2.5 years
Reported as:
Mean · Gram/Liter (g/L)
Change in Hemoglobin From Baseline in the Absence of Red Blood Cell (RBC) Transfusion Over Time
Gram/Liter (g/L)Eltrombopag
Baseline70.4 ± 13.95
D92 Week134.9 ± 11.91
D183 Week268.8 ± 17.08
Extension W3919.3 ± 22.29
Extension W5224.0 ± 21.11
Extension W7832.8 ± 19.58
Extension W10434.4 ± 20.44
Extension W13031.6 ± 16.99
Extension W15616.0 ± NA
Withdrawal-3.0 ± 13.85
Last Assessment On-Therapy10.0 ± 20.14
SecondaryChange in Neutrophil Count From Baseline in the Absence of Granulocyte-colony Stimulating Factor (G-CSF) Over Time

The changes in observed values for Neutrophil Count were summarized. The measurements were followed up to Week 26 and thereafter in the extension part (Up to the launch of the product after approval, which will be approximately up to two and a half years). Only descriptive analysis done.

Time frame:
Up to 2.5 years
Reported as:
Mean · Giga/Liter (Gi/L)
Change in Neutrophil Count From Baseline in the Absence of Granulocyte-colony Stimulating Factor (G-CSF) Over Time
Giga/Liter (Gi/L)Eltrombopag
Baseline0.8247 ± 0.47985
D92 Week130.3321 ± 0.51398
D183 Week260.2046 ± 0.43640
Extension W390.4537 ± 0.87231
Extension W520.5236 ± 0.58529
Extension W780.8579 ± 0.62320
Extension W1040.6312 ± 1.05205
Extension W1301.1835 ± 1.97999
Extension W156-0.1712 ± NA
Withdrawal0.3246 ± 0.72222
Last Assessment On-Therapy0.4307 ± 1.22084
SecondaryHematological Response at Week 13 in Terms of the Platelet Count, Hemoglobin Level and Neutrophil Count

The frequency and percentage were calculated with 95% confidence interval (CI) of responses (which meet each response criteria) of platelet count, hemoglobin and neutrophil count at Week 13.

Time frame:
Week 13
Reported as:
Number · Percentage of participants
Hematological Response at Week 13 in Terms of the Platelet Count, Hemoglobin Level and Neutrophil Count
Percentage of participantsEltrombopag
Hematological Response at Week 13 in Terms of the Platelet Count, Hemoglobin Level and Neutrophil Count61.9 (38.4 to 81.9)
SecondaryDuration of Hematological Response in Participants Who Responded at the Week 13

The duration of haematological response was defined, for subjects who responded at the Week 13 visit, as the number of months from the first date of a response until the first date of a relapse or the date the subject was last assessed. Only subjects with at least 2 response assessments were included in the duration of response assessment. The measurements were followed up to Week 26 and thereafter in the extension part (Up to the launch of the product after approval, which will be approximately up to two and a half years). Only descriptive analysis done.

Time frame:
Up to 2.5 years
Reported as:
Median · Months
Duration of Hematological Response in Participants Who Responded at the Week 13
MonthsEltrombopag
Hematological Response10.68 (1.64 to 28.32)
Platelet/Platelet Transfusion32.62 (32.62 to 32.62)
Hemoglobin/RBC Transfusion Response19.19 (5.54 to 28.37)
Neutrophils Response3.02 (1.64 to 4.63)
SecondaryVolume of (Platelet and RBC) Transfusion in Each Period

The amount of blood transfusion (platelets, RBC) were summarized. The measurements were followed up to Week 26 and thereafter in the extension part (Up to the launch of the product after approval, which will be approximately up to two and a half years). Only descriptive analysis done.

Time frame:
Day 1, Day 92 (Week 13), Day 183 (Week 26), Extension W39 and Extension W52
Reported as:
Mean · milliliter (mL)
Volume of (Platelet and RBC) Transfusion in Each Period
milliliter (mL)Eltrombopag
Day 1 (Platelets)600.0 ± 309.84
Day 1 (RBC)1663.2 ± 1083.31
Day 92 (Week 13) (Platelets)400.0 ± 438.18
Day 92 (Week 13) (RBC)1152.9 ± 978.59
Day 183 (Week 26) (Platelets)280.0 ± 389.87
Day 183 (Week 26) (RBC)800.0 ± 1131.37
Extension W39 (Platelets)0.0 ± 0.00
Extension W39 (RBC)300.0 ± 848.53
Extension W52 (Platelets)0.0 ± 0.00
Extension W52 (RBC)400.0 ± 1131.37
SecondaryFrequency of (Platelet and RBC) Transfusion in Each Period

The frequency of blood transfusion (platelets, RBC) were summarized. The measurements were followed up to Week 26 and thereafter in the extension part (Up to the launch of the product after approval, which will be approximately up to two and a half years). Only descriptive analysis done.

Time frame:
Day 1, Day 92 (Week 13), Day 183 (Week 26), Extension W39 and Extension W52
Reported as:
Mean · Tansfusion
Frequency of (Platelet and RBC) Transfusion in Each Period
TansfusionEltrombopag
Day 1 (Platelets)3.0 ± 1.55
Day 1 (RBC)4.1 ± 2.51
Day 92 (Week 13) (Platelets)2.0 ± 2.19
Day 92 (Week 13) (RBC)2.9 ± 2.41
Day 183 (Week 26) (Platelets)1.4 ± 1.95
Day 183 (Week 26) (RBC)1.9 ± 2.64
Extension W39 (Platelets)0.0 ± 0.00
Extension W39 (RBC)0.8 ± 2.12
Extension W52 (Platelets)0.0 ± 0.00
Extension W52 (RBC)0.9 ± 2.47
SecondaryPercentage of Participants With Reduced Volume of Transfusion (Platelet and RBC)

The proportion of the participants for whom the amount of blood transfusion (platelets and RBC) is decreased was measured and reported as a percentage. The measurements were followed up to Week 26 and thereafter in the extension part (Up to the launch of the product after approval, which will be approximately up to two and a half years). Only descriptive analysis done. This analysis was performed for the subjects who were baseline transfusion dependent.

Time frame:
Up to 2.5 years
Reported as:
Number · Percentage of participants
Percentage of Participants With Reduced Volume of Transfusion (Platelet and RBC)
Percentage of participantsEltrombopag
Platelet Transfusion Decrease83.3
RBC Transfusion Decrease73.7
SecondaryPercentage of Participants Who Become Transfusion (Platelet and RBC) Independent

The proportion of participants for whom blood transfusion (platelets and RBC) became unnecessary was measured and reported as a percentage. The measurements were followed up to Week 26 and thereafter in the extension part (Up to the launch of the product after approval, which will be approximately up to two and a half years). Only descriptive analysis done. This analysis was performed for the subjects who were baseline transfusion dependent.

Time frame:
Up to 2.5 years
Reported as:
Number · Percentage of participants
Percentage of Participants Who Become Transfusion (Platelet and RBC) Independent
Percentage of participantsEltrombopag
Platelet Transfusion Independence66.7
RBC Transfusion Independence47.4
SecondaryLong-term Safety and Tolerability of Eltrombopag

The frequency and percentage of subjects who experienced adverse events (AEs), serious adverse events (SAEs) and deaths by primary system organ class (SOC) and MedDRA preferred term were summarized.

Time frame:
Up to 30 days after last dose of study treatment
Reported as:
Number · Percentage of participants
Long-term Safety and Tolerability of Eltrombopag
Percentage of participantsEltrombopag
AEs by Primary SOC (SOC)100
Grade 1 AEs by Primary SOC (SOC)85.7
Grade 2 AEs by Primary SOC (SOC)81.0
Grade 3 AEs by Primary SOC (SOC)42.9
Grade 4 AEs by Primary SOC (SOC)4.8
SAEs by Primary System Organ Class (SOC)28.6
SecondaryNumber of Participants With Bleeding Events and Severity of Bleeding

The measurements were followed up to Week 26 and thereafter in the extension part.

Time frame:
Up to 30 days after last dose of study treatment
Reported as:
Number · N° of Participants with Bleeding events
Number of Participants With Bleeding Events and Severity of Bleeding
N° of Participants with Bleeding eventsEltrombopag
AE Bleeding - On Treatment11
Grade 1 AE Bleeding - On Treatment9
Grade 2 AE Bleeding - On Treatment2
AE Bleeding - Followup Phase6
Grade 1 AE Bleeding - Followup Phase5
Grade 2 AE Bleeding - Followup Phase1
SAE Bleeding - On Treatment0
SAE Bleeding - Followup Phase3
Grade 1 SAE Bleeding - Followup Phase2
Grade 2 SAE Bleeding - Followup Phase1
SecondaryMaximum Observed Plasma Concentration (Cmax) for Eltrombopag

At some study sites, full blood sampling for pharmacokinetic (PK) evaluation of Eltrombopag was performed on Day 14 to calculate Cmax, tmax, AUC(0-t), and AUC(0-tau). PK parameters were calculated from plasma concentration-time data using non-compartmental methods.

Time frame:
Day 14 at 25 mg QD (-0.05, 0.15, 0.30, 0.45, 1.00, 1.30 and 24.00), at 50,75 and 100 mg QD (pre-dose)
Reported as:
Mean · nanogram per milliliter (ng/mL)
Maximum Observed Plasma Concentration (Cmax) for Eltrombopag
nanogram per milliliter (ng/mL)Eltrombopag
Maximum Observed Plasma Concentration (Cmax) for Eltrombopag6410 ± 4200
SecondaryTime to Reach the Maximum Plasma Concentration (Tmax) for Eltrombopag

At some study sites, full blood sampling for pharmacokinetic (PK) evaluation of Eltrombopag was performed on Day 14 to calculate Cmax, tmax, AUC(0-t), and AUC(0-tau). PK parameters were calculated from plasma concentration-time data using non-compartmental methods.

Time frame:
Day 14 at 25 mg QD (-0.05, 0.15, 0.30, 0.45, 1.00, 1.30 and 24.00), at 50,75 and 100 mg QD (pre-dose)
Reported as:
Median · Hour
Time to Reach the Maximum Plasma Concentration (Tmax) for Eltrombopag
HourEltrombopag
Time to Reach the Maximum Plasma Concentration (Tmax) for Eltrombopag2.00 (1.90 to 7.58)
SecondaryArea Under the Concentration-time Curve From Time Zero (Pre-dose) to Last Time of Quantifiable Concentration Within a Subject Across All Treatments (AUC 0-t) and Over the Dosing Interval (AUC 0-tau) for Eltrombopag

At some study sites, full blood sampling for pharmacokinetic (PK) evaluation of Eltrombopag was performed on Day 14 to calculate Cmax, tmax, AUC(0-t), and AUC(0-tau). PK parameters were calculated from plasma concentration-time data using non-compartmental methods.

Time frame:
Day 14 at 25 mg QD (-0.05, 0.15, 0.30, 0.45, 1.00, 1.30 and 24.00), at 50,75 and 100 mg QD (pre-dose)
Reported as:
Mean · Hours*nanograms/milliliter (hr*ng/mL)
Area Under the Concentration-time Curve From Time Zero (Pre-dose) to Last Time of Quantifiable Concentration Within a Subject Across All Treatments (AUC 0-t) and Over the Dosing Interval (AUC 0-tau) for Eltrombopag
Hours*nanograms/milliliter (hr*ng/mL)Eltrombopag
AUC(0-t)123000 ± 92900
AUC(0-tau)99200 ± 119000
SecondaryMean Change in Eltrombopag Concentration in Pharmacokinetic Serum Samples Over Time at Days 14 and 15

At every study center, blood samples was be collected on Day 15 of multiple doses of eltrombopag 25 mg to determine the plasma eltrombopag concentration prior to the next dose (trough concentration). In addition, one-point pre-dose blood sampling was performed at every study center on Day 15 of multiple doses of eltrombopag 50 mg, 75 mg and 100 mg to determine trough concentrations. PK parameters were calculated from plasma concentration-time data using non-compartmental methods.

Time frame:
Day 14 (pre-dose, 1, 2, 4, 6, 8 and 24 post-dose), Day 15 (pre-dose)
Reported as:
Mean · nanogram per milliliter (ng/mL)
Mean Change in Eltrombopag Concentration in Pharmacokinetic Serum Samples Over Time at Days 14 and 15
nanogram per milliliter (ng/mL)Eltrombopag
Eltrombopag 25 mg (Day 14) - 0Hr4530 ± 3870
Eltrombopag 25 mg (Day 14) - 1Hr5240 ± 3740
Eltrombopag 25 mg (Day 14) - 2Hr5980 ± 3990
Eltrombopag 25 mg (Day 14) - 4Hr5870 ± 3870
Eltrombopag 25 mg (Day 14) - 6Hr5720 ± 4130
Eltrombopag 25 mg (Day 14) - 8Hr5430 ± 4170
Eltrombopag 25 mg (Day 14) - 24Hr4390 ± 3680
Eltrombopag 25 mg (Day 15) - 0Hr3730 ± 2430
Eltrombopag 50 mg (Day 15) - 0Hr8530 ± 6410
Eltrombopag 75 mg (Day 15) - 0Hr15200 ± 12000
Eltrombopag 100 mg (Day 15) - 0Hr19300 ± 15000

Adverse events

Collected over Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit up to approximately 3 years and 1 month.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Eltrombopag0/21 (0%)6/21 (28.6%)20/21 (95.2%)
Most frequent serious events
Most frequent serious events
EventEltrombopag
Decreased appetiteMetabolism and nutrition disorders2/21
Retinal detachmentEye disorders1/21
Abdominal painGastrointestinal disorders1/21
EnterocolitisGastrointestinal disorders1/21
Hepatic function abnormalHepatobiliary disorders1/21
Fibrin D dimer increasedInvestigations1/21
Back painMusculoskeletal and connective tissue disorders1/21
Spinal osteoarthritisMusculoskeletal and connective tissue disorders1/21
Most frequent other events
Showing 10 of 23
Most frequent other events
EventEltrombopag
NasopharyngitisInfections and infestations8/21
Abdominal pain upperGastrointestinal disorders4/21
Hepatic function abnormalHepatobiliary disorders4/21
PyrexiaGeneral disorders3/21
GastroenteritisInfections and infestations3/21
UrticariaSkin and subcutaneous tissue disorders3/21
HypertensionVascular disorders3/21
DiarrhoeaGastrointestinal disorders2/21
DyspepsiaGastrointestinal disorders2/21
Gastrooesophageal reflux diseaseGastrointestinal disorders2/21

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Eltrombopag
Median53.0 (19 to 79)
Sex: Female, Male
Sex: Female, Male(Participants)Eltrombopag
Female12
Male9
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Eltrombopag
American Indian or Alaska Native0
Asian21
Native Hawaiian or Other Pacific Islander0
Black or African American0
White0
More than one race0
Unknown or Not Reported0
08

Study locations

12 sites
  • Novartis Investigative Site
    Aichi, 453-8511, Japan
  • Novartis Investigative Site
    Aichi, 460-0001, Japan
  • Novartis Investigative Site
    Hyogo, 664-8540, Japan
  • Novartis Investigative Site
    Ibaraki, 305-8576, Japan
  • Novartis Investigative Site
    Ishikawa, 920-8641, Japan
  • Novartis Investigative Site
    Miyagi, 981-1293, Japan
  • Novartis Investigative Site
    Okayama, 700-0962, Japan
  • Novartis Investigative Site
    Osaka, 530-0012, Japan
  • Novartis Investigative Site
    Osaka, 543-8555, Japan
  • Novartis Investigative Site
    Osaka, 565-0871, Japan
  • Novartis Investigative Site
    Tochigi, 329-0498, Japan
  • Novartis Investigative Site
    Tokyo, 141-8625, Japan
09

References and documents

Publications

  • Yamazaki H, Ohta K, Iida H, Imada K, Obara N, Tokumine Y, Tomiyama Y, Usuki K, Imajo K, Miyamura K, Sasaki O, Fanghong Z, Hattori T, Tajima T, Matsuda A, Nakao S. Hematologic recovery induced by eltrombopag in Japanese patients with aplastic anemia refractory or intolerant to immunosuppressive therapy. Int J Hematol. 2019 Aug;110(2):187-196. doi: 10.1007/s12185-019-02683-1. Epub 2019 Jun 10. PubMed 31183813 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2014 to primary completion in Sep 2015, 13 months.

Results were first posted in May 2019, 3 years 7 months after primary completion.

Of 60 phase 2 interventional studies under Anemia, Aplastic, half reached primary completion within 76 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 104. This study's 13 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 22, 2014
First posted
May 28, 2014
StartActual
Jul 23, 2014
Primary completionActual
Sep 10, 2015
CompletionActual
Sep 5, 2017
Results first posted
May 3, 2019
Last update
May 3, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 3, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02148133
Responsible party
Sponsor
First posted
May 28, 2014
Start date
Jul 23, 2014
Primary completion
Sep 10, 2015
Completion
Sep 5, 2017
Results posted
May 3, 2019
Last update
May 3, 2019

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Eltrombopag

Start the discussion